Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in the United States
Participants receiving routine rVWF prophylaxis in this study experienced reduced ABR and HCRU versus the baseline period, indicating that rVWF prophylaxis may result in improved outcomes in people with VWD across all subtypes.
Authors
- Sanjana Sundaresan (ORCID: https://orcid.org/0000-0002-4324-1731)
- Jorge Caicedo
- Bethany A. Jones (ORCID: https://orcid.org/0000-0001-8872-5847)
- Maissaa Janbain (ORCID: https://orcid.org/0000-0002-4176-9110)
- Natalia Nieto
- Elyse Swallow (ORCID: https://orcid.org/0000-0002-1634-142X)
- Jonathan Roberts (ORCID: https://orcid.org/0000-0002-9415-9543)
- Jessica R. Marden (ORCID: https://orcid.org/0000-0001-9108-8711)
Institutions
- Tulane University (US)
- Illinois College (US)
- Foundation Center (US)
- University of Illinois Chicago (US)
Publication Details
- Journal
- Expert Review of Hematology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1080/17474086.2025.2504956
- Citations
- 1
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Takeda Pharmaceuticals U.S.A.